ABSTRACT Late-onset male hypogonadism (LOH) is a clinical and biochemical syndrome associated with advancing age and characterised by low serum testosterone concentrations. An understanding of the physiology of androgens in the ageing man is essential for the appropriate diagnosis of LOH. Clinical assessment of androgen status relevant to clinical biochemists and chemical pathologists is outlined in this review. Laboratory investigations of androgen status in men are not without pitfalls and the authors highlight problems associated with measuring and calculating serum testosterone and its fractions, the interpretation of which can be problematic. Current clinical guidelines and recommendations regarding the diagnosis and monitoring of LOH are also summarised.
INTRODUCTION
Late-onset male hypogonadism (LOH), also known as male menopause or androgen decline in the ageing male in the literature, is a clinical and biochemical syndrome associated with advancing age and characterised by testosterone deficiency and symptoms or signs typical of testosterone deficiency. 1 2 In the past decade, laboratories have seen a marked increase in requests for tests that assess the gonadal status in the ageing man. This trend has partly arisen as a result of the recognition that testosterone concentrations diminish with age even in 'healthy' men and the possibility that some of the common clinical features associated with the ageing process, such as loss of libido, erectile dysfunction, tiredness, loss of muscle mass and mood changes, may be attributable to androgen deficiency. In addition, a link between low testosterone status and many common diseases found in the elderly population has been suggested; these diseases include osteoporosis, Alzheimer 's disease, type 2 diabetes, ischaemic heart disease, hypercholesterolaemia and hypertension. 3e5 When hypogonadism is suspected in an adult man, serum total testosterone (total T) is usually the initial laboratory investigation for the assessment of androgen status in the routine clinical setting. The measurement of specific fractions of serum testosterone such as free (unbound) testosterone (free T) or bioavailable testosterone (BAT; total of unbound and albumin-bound testosterone fractions) is increasingly used to assess androgen status. Unfortunately measurement of free T concentrations is technically demanding and no simple reliable method is currently available for routine clinical use. To estimate free T and BAT concentrations in serum, multiple formulae have been reported in the literature. The use of such formulae is thought to be preferable to using total T for the diagnosis of hypogonadism in the adult man when serum total T concentration is equivocal.
In this review, we shall discuss issues in relation to LOH that are relevant to chemical pathologists, clinical biochemists and other laboratory staff. Current knowledge regarding the physiology of androgens in the ageing man, together with the clinical situations where assessment of androgen status is indicated, will be outlined. Problems associated with measuring and calculating serum testosterone and its fractions will be highlighted. Finally, we shall summarise current recommendations regarding the diagnosis of LOH.
TRANSPORT, METABOLISM AND ACTION OF TESTOSTERONE
In men, about 60% of testosterone circulates in blood strongly bound to sex hormone binding globulin (SHBG) while around 38% is weakly bound to albumin and approximately 2% is unbound (free). These proportions vary somewhat and are dependent on the relative concentrations and affinities of albumin and SHBG. Since a large proportion of circulating testosterone is bound to SHBG, the factors that alter the concentration or affinity of SHBG for testosterone have a significant effect on the circulating total testosterone concentration. Factors that can modify the concentrations of SHBG are shown in box 1.
There is continued debate concerning which components of circulating testosterone are capable of exerting bioactivity on target tissues. Classically, androgens have been considered to exert their effects through interactions with the androgen receptor, which functions as a ligand-dependent transcriptional regulator of androgen-responsive genes. As such, steroid biochemists have traditionally held the view that only the small unbound 'free' fraction can enter cells and exert a biological effect. It has also been generally assumed that testosterone bound to SHBG does not dissociate at all during its passage through capillaries. However, to account for the observation that there is a high hepatic uptake of steroids in the liver, it was postulated that the fraction of steroid that is loosely bound to albumin can also be regarded as 'free' and thus has potential bioactivity. 6 The combined fraction of unbound and albumin-bound testosterone fractions is often known as BAT. 7 8 Few routine clinical laboratories currently measure free testosterone (free T) or BAT since such measurements are technically demanding or unreliable. Instead many laboratories 'calculate' free T or BAT from measured concentrations of total T, SHBG and albumin (see later in this review for methods).
In many tissues, testosterone is converted to the more biologically active androgen 5a-dihydrotestosterone by the two 5a-reductase isoenzymes. 9 Some actions of testosterone may also be mediated through oestrogen receptors after local conversion of testosterone to oestradiol by the enzyme aromatase. It is thus probable that many of the actions of testosterone may be regulated in target tissues by either 5a-reductase or aromatase. 10 Although steroid hormones are widely believed to enter cells by passive diffusion, there may be pathways that allow uptake of protein-bound steroids. Such pathways involve the recognition of carrier proteins by receptors on the cell surface, followed by endocytosis of the carrier proteinesteroid complex. 11 12 Despite these recent observations suggesting that SHBG-bound testosterone may enter target cells, for diagnostic purposes free T and BAT are considered the clinically relevant fractions in serum.
CHANGES IN SERUM TESTOSTERONE AND GONADOTROPHINS WITH AGE
Many cross-sectional 13e15 and longitudinal 16 17 studies have shown that total T, free T and BAT decline with age, while SHBG concentrations increase. As a consequence of the increasing SHBG, the fall in free Tand BATwith increasing age is in general more marked than that of total T. It has been established in one study that after the age of 40 the average agerelated fall in total T is 0.8e1.6% per year whereas free T and albumin-bound T decline with age by 1.7e2.8% and 2.0e2.5% per year, respectively. 17 The age-associated decline in these measures of testosterone occurs in healthy men and in men with chronic illness, although concentrations in healthy men tend to be 10e15% higher than in patients with chronic illness. 17 The reason for the decline in testosterone concentrations with increasing age is not fully understood but multiple mechanisms including primary testicular changes, altered neuroendocrine regulation of Leydig cell function and increase in plasma SHBG binding capacity have been proposed. 18 In contrast, serum luteinising hormone (LH) and folliclestimulating hormone concentrations show a tendency to increase slightly with age but are often not above the reference ranges derived from younger men. 15 17 19 The frequency and amplitude of LH pulses decrease with age but LH release elicited by gonadotrophin-releasing hormone is maintained. 20 21 Furthermore, secretion of testosterone in response to gonadotrophin-releasing hormone or LH infusion also diminishes with age. 21 22 Prolactin concentrations also tend to increase with age and this may indicate a loss of hypothalamic-pituitary regulatory function in the ageing man. 17 The age-related increase in prolactin has been ascribed to a loss in dopamine production, which is the main regulator of prolactin production. 23 Taken together, these observations suggest that both Leydig cell dysfunction and changes in the hypothalamic-pituitary unit may contribute to the gradual decline in serum testosterone commonly seen in ageing men. At the target tissue level, it is possible that older men also have reduced concentrations of androgen receptors, which in turn may explain some of the clinical features of LOH. 24 
DIURNAL CHANGES IN TESTOSTERONE
Serum total T, BAT and free T exhibit a diurnal variation with peak concentrations occurring around 06:00e08:00 and trough concentrations at 18:00e20:00. 25 The fall in these measurements between peak and trough levels is in the order of 40%. This diurnal variation is maintained in healthy men until at least the age of 70 years although peak and trough levels are on average lower in elderly men. Serum SHBG concentrations also show a diurnal variation, with peak concentrations occurring around 16:00 and trough concentrations at around 04:00. As a consequence of these changes it is generally recommended that blood samples for clinical investigation are taken during the early morning when testosterone concentrations are at their maximum.
LABORATORY ASSESSMENT OF TESTOSTERONE CONCENTRATIONS
Measurement of serum testosterone concentration is an important step in the diagnosis of LOH, but it is not entirely clear which serum fraction of testosterone provides the best assessment of gonadal status in men. Methods for measuring or estimating total T, free T and BAT are currently available and discussed below.
Total T
Current clinical guidelines recommend serum total T for the initial laboratory investigation of male gonadal status. 1 5 26 In routine clinical laboratories this is typically carried out using automated immunoassay platforms. Immunoassay methods are in general satisfactory at serum testosterone concentrations found within the reference range for healthy men but may be inaccurate at the lower concentrations found in hypogonadal men and most women. There are method-related differences in terms of accuracy as well as precision for all immunoassays and the currently available immunoassays for testosterone are no exception. 27 Isotope dilution gas chromatographyemass spectrometry (MS) is regarded as the reference method but few laboratories have the ability to perform this in routine use. Liquid chromatographyetandem MS (LC-MS) is becoming more widely available for routine use and is regarded by many as a reliable and accurate means of measuring serum total T. The accuracy of LC-MS methods however depends on the reliability of the sample extraction procedure and calibration.
27 Figure 1 illustrates the between method bias variability in total T for
Box 1 Common causes of altered sex hormone binding globulin (SHBG) concentrations
Increased SHBG < Hyperthyroidism < Hypogonadism (males) < Cirrhosis < Oestrogens < Increasing age < Anticonvulsants < Anorexia nervosa Decreased SHBG < Obesity < Hypothyroidism < Polycystic ovary syndrome < Glucocorticoids < Androgens < Insulin resistance < Diabetes men as determined from the United Kingdom External Quality Assessment Scheme (UKNEQAS). The data show how some methods agree well with LC-MS while others show significant assay bias. Between laboratory bias for laboratories using LC-MS is also apparent, indicating a need for further work to harmonise results generated by LC-MS methods. Such differences between methods also necessitate the use of method-related reference ranges for total T in different laboratories.
Free T
Clinical guidelines have recommended the use of free T concentrations for the diagnosis of LOH in men with equivocal total T. 1 5 28 The measurement of the small free T fraction in serum has proved challenging. 29 The reference method for measuring free T is widely regarded as equilibrium dialysis or ultrafiltration. 30 31 The two methods involve separation of the free T fraction by the use of a semipermeable membrane that only allows passage of the unbound (free T) testosterone fraction. Total T concentration in the dialysate or ultrafiltrate can then be measured using a sensitive immunoassay or tandem MS method. An alternative methodology is to pre-incubate the sample with radioactive testosterone prior to the separation procedure and then calculate the free T as the product of the total T multiplied by the percentage of the dialysable fraction. Routine measurement of free T by any reference method in a busy routine laboratory is impractical because the assays are technically demanding and laborious. The measurement of testosterone in saliva has also been suggested as a means of estimating free T in serum, and studies have reported encouraging results. 32 33 Because the basement membrane of salivary gland excludes serum proteins and free T enters into saliva by passive diffusion, it is thus believed that salivary testosterone reflects serum free T concentrations. However, small amounts of proteins from exudates or blood may be present in saliva, making interpretation of testosterone concentration in saliva difficult. Currently salivary testosterone assays are not widely used in clinical practice and further evaluation is required before their use can be recommended.
Direct analogue assays for free T
Direct analogue assays of free T are commercially available but are not recommended for diagnostic purposes. 1 5 28 The assays use a tracer that is testosterone modified in such a way that the analogue binds to the antibody in the assay but not to serumbinding proteins. If the analogue is chosen carefully and the assay optimised appropriately, the amount of analogue that competitively binds to the antibody is inversely proportional to the 'free T' concentration in the sample. 29 However, results generated by such assays are in general inaccurate and show poor correlation with free T measured by equilibrium dialysis. 34e36 Many of these assays tend to correlate better with total T 29 and most guidelines advise against their use in clinical practice. Due to the lack of accurate and practicable assays for the routine laboratory to measure free T, various methods for the estimation of free T have been reported in the literature and are summarised below.
Free androgen index
Free androgen index (FAI) was first described by Carter et al for the investigation of women presenting with hirsutism 37 and is calculated by the formula: 1003(total T (nmol/l))/(SHBG (nmol/l)). There are a number of advantages in using FAI in estimating free T status in adult women. First, FAI is mathematically easy to calculate. Second, total T and SHBG assays are widely available in routine clinical laboratories. Third, the use of FAI has been confirmed to provide some diagnostic value in women. 38 However, FAI is a dimensionless parameter with little indication of the concentration of circulating free T. Although FAI is frequently applied in clinical practice to estimate free T status in women, it should not be used in men because some of the assumptions inherent in the formula are not applicable to males.
39e41 A key assumption for the derivation of FAI, that is, the binding capacity of SHBG for testosterone is large compared with testosterone concentration, applies to women but not men because of the relatively low concentrations of testosterone and high concentrations of SHBG present in women. 39 Also, at low concentrations of SHBG commonly found in men, FAI overestimates free T. 41 
Calculated free testosterone
At least six different equations have been published for the calculation of serum free T in men (table 1). They can be grouped into two main categories: first, equations based on the law of mass action with the assumption that one ligand (testosterone) binds to two proteins (SHBG and albumin) 34 42 ; second, equations derived from empirical measurements of free T. 31 43 44 All of these calculated free testosterone (CFT) equations involve the measurement of total T and SHBG; in addition, the two equations based on the law of mass action also require albumin concentration. Among these equations, the Vermeulen version is probably the most widely used in the literature and CFT values derived using this equation have been shown to correlate well with free T concentrations measured by equilibrium dialysis in the original study. 34 Other CFT equations have been derived using free T concentrations measured by different methods. 31 43 44 It is important to note that given the same total T, SHBG and albumin concentrations, the various equations can result in CFT values up to approximately 
Bioavailable testosterone
Serum BAT, also known as non-SHBG-bound testosterone, is the fraction of circulating testosterone that is not bound to SHBG. In practice, BAT is generally considered equivalent to the sum of free T and albumin-bound testosterone. Its use is mainly based on the hypothesis that testosterone bound to albumin can readily dissociate from the protein and is available for entry into target tissues. BAT can be either assayed or calculated. It is usually assayed by the precipitation of SHBG and SHBG-bound steroids using ammonium sulfate, followed by direct measurement of testosterone in the supernatant. An alternative method for BAT measurement involves pre-incubation of serum with tritiated testosterone before ammonium sulfate precipitation; the percentage of the radiolabelled tracer remaining in the supernatant is then multiplied by the total T concentration to yield BAT. 25 One disadvantage of BAT measurement is its dependence on adequate SHBG precipitation, temperature and concentration of ammonium sulfate solution used. Also, BAT assays are not easily automated and thus few clinical laboratories routinely measure BAT. Several equations for the calculation of BAT have been proposed and, like CFT equations, they fall into two categories 1 : equations based on the law of mass action 2 34 42 and equations derived from empirical measurement of BAT. 46 47 Giton et al compared calculated BAT with assayed BAT in men and found that correlation between the two BAT values depended to a large extent on the chosen association constants of testosterone for albumin and SHBG. 48 To date, there is no consensus on whether BAT is better than free T as a biochemical marker of androgenicity.
Sex hormone binding globulin
Most routine laboratories do not measure free T or BAT due to the technically demanding nature of these assays; these fractions are instead calculated using the equations described above. In each of these calculations, the concentrations of both SHBG and total T have a marked influence on the calculated results. A number of immunoassay methods are routinely used for SHBG; UKNEQAS data highlight how marked method-related differences in bias can occur between these SHBG assays (figure 2). It is thus important that method-related reference ranges are used for SHBG, and for CFT and BAT calculated based on such measured SHBG concentrations.
CLINICAL EVALUATION OF ANDROGEN STATUS
There is no universally accepted definition of male hypogonadism. Commonly used diagnostic criteria are summarised in box 2. In most cases, a combination of symptoms, signs and laboratory investigations is used to reach a diagnosis. 1 5 Low libido is one of the commonest symptoms experienced by hypogonadal males. 49 50 Depressed mood, lethargy and erectile dysfunction are among the other symptoms associated with LOH (box 3). Questionnaires for symptoms associated with male hypogonadism such as the Androgen Deficiency in Ageing Male 51 and the Ageing Male Symptom Score 52 have been developed to assist the diagnosis of LOH. However, the use of these questionnaires is not widespread in clinical practice and is not recommended by clinical guidelines for the diagnosis of LOH because of low specificity. 12 Some symptoms associated with LOH are indeed not uncommon in the healthy ageing man; for example, a large proportion (up to 35%) of eugonadal men with testosterone >10.5 nmol/l and LH <9.5 U/l in the European Male Ageing Study reported symptoms that are usually associated with hypogonadism. 53 A clear-cut total T or CFT threshold for the identification of symptoms or signs associated with LOH has not been identified; rather, the prevalence of such symptoms and signs increases with decreasing androgen levels. 50 54 It is important to recognise the observation that men who have low serum T concentrations can also be asymptomatic. 55 Estimates of the prevalence of LOH depend on the diagnostic criteria used and thus they vary between studies. In a crosssectional study of 1845 men (aged 47.3612.5 years, mean6SD), 24% and 11% of subjects had total T <10.4 nmol/l and CFT <173 pmol/l respectively, whereas only 5.6% of men in this study met the criteria for symptomatic androgen deficiency. 55 In comparison, men were considered to have androgen deficiency in the Massachusetts Male Ageing Study if they had at least three signs/symptoms and either (1) total T <6.9 nmol/l or (2) total T 6.9e13.9 nmol/l and CFT<309 pmol/l; the prevalence of androgen deficiency in the Massachusetts Male Ageing Study increased from 6.0% at baseline (aged 40e70 years) to 12.3% at follow-up (aged 48e79 years). 56 The prevalence of LOH is also age dependent; for example, in the European Male Ageing Study (defined as at least three sexual symptoms in the presence of total T <11 nmol/l and CFT <220 pmol/l) it increased from 0.1% in men aged 40e49 years to 5.1% in those aged 70e79 years (overall prevalence 2.1%).
The Endocrine Society Clinical Practice Guideline 2010 recommends that a diagnosis of androgen deficiency should only be made in men with consistent symptoms or signs, and unequivocally low serum testosterone levels. 5 Many crosssectional and longitudinal studies have shown that serum concentrations of testosterone and other androgens in men decrease gradually with age from the fourth or fifth decade of life. It is not universally agreed that reference ranges derived from young healthy men can be applied to all adult men. 41 There is no consensus whether age-related reference ranges of testosterone should be used in the diagnosis of LOH. Published studies also disagree on what cut-off levels of total T, CFT or BAT can be classified as unambiguously low for the purpose of clinical diagnosis. Also, a single threshold below which symptoms of LOH and adverse health outcomes occur has not been defined. 5 Without considering the differences in assay-related performance, various lower limits of reference range for morning total T have been reported or used in the literature, and these range from 9.4 to 12 nmol/l. 1 41 50 57 For practical purpose, a total T of 12 nmol/l or more is generally considered not deficient. 1 26 It is, however, widely accepted that total T should be measured on at least two occasions before a diagnosis of LOH is made. When total T is borderline low (eg, 8e12 nmol/l) or an abnormal SHBG concentration is suspected, CFT or BAT may be useful in the diagnosis of LOH. 15 Yet, there are no universally accepted threshold levels of CFT or BAT; reference ranges derived from established assays and method/equation for CFT/BAT based on a well-defined normal population should be used. 41 There is little evidence to indicate that CFT is a better estimation of free T than BAT, or vice versa, for the diagnosis of LOH.
Measurement of follicle-stimulating hormone and LH can help differentiate between primary (testicular) and secondary (hypothalamic-pituitary) hypogonadism 1 5 and should be included as part of the laboratory diagnostic profile in men with persistently low testosterone. In men with secondary hypogonadism, investigation of other pituitary functions, for example serum prolactin, is usually indicated.
An inverse relationship between body weight and total T was first reported in the 1970s. 58 Subsequent studies have confirmed that total T decreases with increasing body mass index (BMI) 14 16 59 and is positively correlated with serum SHBG concentrations. 60 It is thus believed that the negative association between total T and BMI is to a large extent due to reduced SHBG synthesis in liver and serum SHBG concentrations in obese men. Other explanations of decreased testosterone levels in obese men have also been proposed. 61 The oestrogen hypothesis suggests that in obese subjects increased aromatase activity in body fat can metabolise testosterone to oestrogen and this action of aromatase tends to diminish testosterone concentrations and also increases oestrogen production, which in turn may attenuate the rise in LH that would be expected when testosterone levels fall. In addition, obesity can lead to increased serum leptin concentrations, which may act on the hypothalamic-pituitary unit and Leydig cells in the testes, leading to reduced serum testosterone concentrations in men. 61 Because of a reduction in serum SHBG concentrations often seen in obese subjects, the reduction of free testosterone with increasing BMI may be less marked than total T. Therefore, measurement or estimation of free T may be useful in obese men with borderline low total T. Type 2 diabetes (T2DM) is a recognised risk factor for male hypogonadism. 1 Multiple studies have shown that T2DM is associated with lower total T in men compared with controls even after adjustment for age and BMI.
62e65 Serum free T levels are also lower in T2DM patients than in controls. 65 T2DM patients tend to be overweight and decreased SHBG concentrations can at least partly explain the lower total T. Studies have demonstrated that testosterone replacement therapy improved glycaemic control or insulin sensitivity but more long-term studies are awaited to determine the benefits of testosterone replacement in T2DM patients. 5 65 In patients on testosterone replacement therapy, total T should be raised to approximately mid-normal levels found in healthy, young men. 1 5 The recent joint UK societies' guidelines recommend a minimum total T of 15 nmol/l for symptomatic improvement, 26 whereas a target total T of 400e700 ng/dl (13.9e24.3 nmol/l) 1 week after testosterone enanthate or cypionate injection has been suggested by the Endocrine Society (USA) guidelines. 5 The Association of British Clinical Diabetologists recommends monitoring of testosterone therapy at 3, 6 and 12 months and then annually in patients with diabetes, 2 whereas the Endocrine Society (USA) guidelines suggest monitoring of testosterone 3e6 months after initiation of replacement therapy. 5 There is currently not enough evidence to indicate that free T, CFT or BAT is useful in the monitoring of patients on testosterone replacement therapy. Other investigations useful for the monitoring of patients on testosterone replacement therapy include haematological assessment using haematocrit. 5 26 There is no conclusive evidence that testosterone replacement therapy increases the risk of prostate cancer or benign prostatic hyperplasia. 1 It is, however, recommended that digital rectal examination and baseline prostate-specific antigen be performed to assess the risk of prostate cancer before testosterone treatment. 15 The suggested frequency of prostate-specific antigen monitoring varies between different guidelines. 
FUTURE PERSPECTIVES
The clinical benefits and risks of implementing testosterone replacement therapy is an area of intense ongoing research, but there are still many unanswered questions with regard to when such therapy should be given and situations where the clinical benefit outweighs the risks of intervention therapy. 66 67 Studies that investigate non-sexual beneficial effects of testosterone replacement on conditions such as insulin resistance, hyperlipidaemia and obesity, are also warranted.
To our knowledge there are no data from external quality assessment schemes that compare different methods or equations for free T, salivary testosterone or BAT. Standardisation of testosterone assays is in progress and reference methods developed at the Centers for Disease Control and Prevention, USA, are expected to allow other laboratories and manufacturers of assays to calibrate their methods. 68 It is anticipated that standardisation of total T assays will improve the diagnosis and monitoring of LOH.
Take-home messages < Serum total testosterone is usually the initial laboratory investigation for the assessment of androgen status in men suspected of late-onset hypogonadism. < Estimation of serum free testosterone concentrations by parameters such as calculated free testosterone or bioavailable testosterone is indicated in men who have equivocal total testosterone concentrations. Free androgen index should no longer be reported for men. < Androgen deficiency should only be diagnosed in patients with low testosterone levels on at least two occasions and symptoms or signs suggestive of late-onset hypogonadism. < There is currently no general consensus on how laboratory tests should be used to monitor patients on testosterone supplements.
